Golocdacimab

Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential to be used in the treatment of type 2 diabetes[1].

Product Specifications

CAS Number

[2418540-63-1]

Product Name Alternative

MEDI6570

UNSPSC

12352203

Target

LOX-1

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/golocdacimab.html

Purity

99.11

Solubility

10 mM in DMSO

Smiles

[Golocdacimab]

Molecular Weight

(146.64 kDa)

References & Citations

[1]Vavere AL, et al. Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. J Am Heart Assoc. 2023 Feb 7;12 (3) :e027540.|[2]Varma V, et al. Identification of Response Biomarkers and Signaling Pathways Associated With the LOX-1 Blockade by MEDI6570 in Type 2 Diabetes[J]. Circulation, 2022, 146 (Suppl_1) : A11971-A11971.|[3]Canoneo C N. Contributions of Macrophages in the Disease Pathology of Myocardial Infarction and Atherosclerosis: A Literature Review[J]. Undergraduate Research in Natural and Clinical Science and Technology Journal, 2024, 8: 1-10.